Feasibility of clinical dendritic cell vaccination in acute myeloid leukemia.
Dendritic cells (DC) are increasingly being utilized for anti-cancer therapy. Acute myeloid leukemia (AML) blasts are able to differentiate towards leukemia-derived DC enabling efficient presentation of known and unknown leukemic antigens. Advances in culture techniques and AML-DC characterization justify clinical application. However, clinical trials using AML-DC are hampered by patient inclusion criteria which allow selective entering of patients in second complete remission. Clinical relevant responses to DC-based immunotherapy are likely to only occur in non-end-stage patients. Application in early stage disease is mandatory to permit ultimate proof of clinical benefit of AML-DC vaccination strategy.
Houtenbos
Ilse
I
Department of Hematology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Westers
Theresia M
TM
Ossenkoppele
Gert J
GJ
van de Loosdrecht
Arjan A
AA
D000208:Acute Disease; D019496:Cancer Vaccines / Q000276:immunology*; D003713:Dendritic Cells / Q000276:immunology / Q000637:transplantation*; D005240:Feasibility Studies; D006801:Humans; D016219:Immunotherapy, Adoptive; D007951:Leukemia, Myeloid / Q000276:immunology* / Q000628:therapy*
D019496:Cancer Vaccines